FDA Approves GW’s Cannabis-Based Drug Epidiolex for the Treatment of Rare, Severe Forms of Epilepsy

London, UK, Carlsbad, CA, June 25, 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol) oral …

More From BioPortfolio on "FDA Approves GW’s Cannabis-Based Drug Epidiolex for the Treatment of Rare, Severe Forms of Epilepsy"